Jason Fife
Family Medicine · Layton, UTNPI 1790761740
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 91 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by AbbVie at 31.5% of the total. Reporting peaked in 2022 at $400 and has fallen 91.8% since, to $33 in 2024.
Across 91 payments — averaging $15.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$438
- E.r. Squibb & Sons, L.L.C.$125
- Astellas Pharma US Inc$112
- Novo Nordisk$91
- Lilly USA, LLC$78
- Pfizer$69
- plus $476 from 18 others
What the payments were for
- Food & beverage$1,37699%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 37 | $438 |
| E.r. Squibb & Sons, L.L.C. | 1 | $125 |
| Astellas Pharma US Inc | 7 | $112 |
| Novo Nordisk | 6 | $91 |
| Lilly USA, LLC | 6 | $78 |
| Pfizer | 4 | $69 |
| Johnson & Johnson | 3 | $56 |
| Merck | 3 | $53 |
| Amarin Pharma, Inc. | 3 | $47 |
| Teva Pharmaceuticals USA, Inc. | 3 | $37 |
| Amgen | 2 | $37 |
| Dynavax Technologies Corporation | 2 | $30 |
| Biohaven Pharmaceuticals, Inc. | 2 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $21 |
| Boehringer Ingelheim | 1 | $20 |
| Genentech USA, Inc. | 1 | $20 |
| Phadia US Inc. | 1 | $19 |
| Jazz Pharmaceuticals Inc. | 1 | $18 |
| Alfasigma USA, Inc. | 1 | $18 |
| GSK | 1 | $16 |
| AstraZeneca | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Lucid Diagnostics Inc. | 1 | $14 |
| Impel Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPDIVO$125
How this compares
$1,388 in reported general payments places this provider in the 65th percentile of 928 family medicine providers in Utah.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atorvastatin Calcium | 22 | $226 |
| Levothyroxine Sodium | 12 | $149 |
| Losartan Potassium | 12 | $131 |
| Lisinopril | 11 | $119 |
| Pantoprazole Sodium | 12 | $106 |
| Rosuvastatin Calcium | 11 | $50 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Layton
- Courtney NelsonLayton$190K
- David ButtersLayton$189K
- Layne BarkerLayton$13K
- Johnnie CookLayton$9K
- Kevin GardnerLayton$9K
- Jared MorrisLayton$8K
- Jeffery DegrauwLayton$8K
- Rachel HobbsLayton$8K
- Marc AndersonLayton$8K
- Michael SchaellingLayton$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.